Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?

Executive Summary

Like biosimilar candidates Zarxio and Inflectra before it, Amgen's ABP 501 enters its advisory committee review with FDA's full-throated endorsement.


Related Content

Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?
Biosimilar Sponsors May Be Going Overboard On Clinical Data, FDA Says
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar
Biosimilar Doubleheader: Amgen's Humira Competitor Pitching First To FDA
Biosimilar Enbrel: Sandoz, FDA Panel Bring Experience To TNF-Inhibitor Review
Amgen's Humira Patent Challenge May Move To Court After PTO Board Declines Review


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts